We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Bayer’s Stivarga Wins Priority Review for Gastrointestinal Stromal Tumors
Bayer’s Stivarga Wins Priority Review for Gastrointestinal Stromal Tumors
November 2, 2012
Bayer HealthCare and Onyx Pharmaceuticals have won priority review for Stivarga to treat metastatic and/or unresectable gastrointestinal stromal tumors.
